Medicinal Products

640. Deputy Ken O'Flynn asked the Minister for Health whether her Department has undertaken any assessment of the patient safety, treatment interruption or cost implications arising from medicines shortages in the past three years; if so, the findings of that assessment; and if not, whether such an assessment will now be commissioned [13766/26]

641. Deputy Ken O'Flynn asked the Minister for Health whether her Department has issued formal policy guidance to the Health Service Executive or to the National Centre for Pharmacoeconomics regarding the appropriate time horizon to be applied in health technology assessments where medicines are intended to reduce the long-term incidence of chronic diseases such as type 2 diabetes and cardiovascul…

672. Deputy Pádraig Rice asked the Minister for Health the number of people on a waiting list for pre-exposure prophylaxis, by clinic; and the wait time to be offered a new appointment in each clinic, in tabular form. [13935/26]

673. Deputy Pádraig Rice asked the Minister for Health to list all public pre-exposure prophylaxis clinics; and to identify the sites in which waiting lists are closed to new self-referrals, in tabular form. [13936/26]

674. Deputy Pádraig Rice asked the Minister for Health the funding allocated to public pre-exposure prophylaxis services to expand capacity, reduce waiting lists and ensure that the waiting lists in all public clinics are open to new self-referrals; and if she will make a statement on the matter. [13937/26]

675. Deputy Pádraig Rice asked the Minister for Health if a new model of pre-exposure prophylaxis will be considered, given the strain on existing clinics (details supplied); if she will review this model; and if she will make a statement on the matter. [13938/26]

280. Deputy Marie Sherlock asked the Minister for Health the reason that preservative-free cosopt eye drops have not been made available on the drugs payment scheme given that it is being prescribed to patients in Ireland; the reason that the licence for preservative-free cosopt drops was withdrawn by the Health Products Regulatory Authority; and if she will make a statement on the matter. [13130/…

287. Deputy Liam Quaide asked the Minister for Health her plans to add Acarizax to the reimbursement list; and if she will make a statement on the matter. [13176/26]

1078. Deputy Conor D. McGuinness asked the Minister for Health the steps her Department is taking to ensure that the price of mounjaro is consistent across all outlets, does not vary widely depending on the outlet which the patient seeks it from, and that the cost of this medicine is not a barrier to those patients for whom it is a necessity; and if she will make a statement on the matter. [11772/…

575. Deputy David Cullinane asked the Minister for Health her views on matters raised in correspondence (details supplied); if the bexcero vaccine has been examined and will be made available through such clinics; and if she will make a statement on the matter. [11338/26]

608. Deputy Peter 'Chap' Cleere asked the Minister for Health if the medicine skyclaris/ omaveloxalone will be reimbursed by the HSE as it is the only drug approved to treat Freidreicsh’s ataxia; and if she will make a statement on the matter. [11491/26]

309. Deputy Mark Wall asked the Minister for Health the steps being taken to ensure urgent access to welireg (belzutifan) for a young adult with von Hippel-Lindau disease in County Kildare (details supplied) where clinicians advise that delay risks irreversible loss of neurological and functional ability; and if she will make a statement on the matter. [10622/26]

315. Deputy Ken O'Flynn asked the Minister for Health whether the Health Service Executive has completed, or is in the process of completing, any National Centre for Pharmacoeconomics Rapid Review, Health Technology Assessment, or other formal evaluation for tirzepatide (mounjaro) and semaglutide (wegovy) for obesity or weight management; the date on which each assessment commenced; the current st…

316. Deputy Ken O'Flynn asked the Minister for Health whether the Health Service Executive or her Department has prepared, commissioned, received, or reviewed any cost-effectiveness analysis, budget impact analysis, or economic model relating to the use of GLP-1 receptor agonist medicines for obesity or weight management, including semaglutide and tirzepatide; whether any such analysis includes mo…

317. Deputy Ken O'Flynn asked the Minister for Health to outline the policy or decision framework used by the Health Service Executive when considering prevention-based outcomes, including reductions in the future incidence of type 2 diabetes and cardiovascular disease, in medicines reimbursement decisions under the Health (Pricing and Supply of Medical Goods) Act 2013; and whether the Department …

318. Deputy Ken O'Flynn asked the Minister for Health whether her Department has undertaken or commissioned any assessment of the equity implications of current access arrangements for GLP-1 receptor agonist medicines for obesity or weight management, including the extent to which access is determined by capacity to pay out of pocket rather than clinical need; and whether the forthcoming national …

320. Deputy Ken O'Flynn asked the Minister for Health the current policy position of her Department on whether GLP-1 receptor agonist medicines for obesity or weight management should be eligible for reimbursement under the Drugs Payment Scheme, subject to health technology assessment and clinical governance; whether any policy review is under way in the context of the development of the new natio…

321. Deputy Ken O'Flynn asked the Minister for Health whether the national obesity strategy currently in development will explicitly address the role of pharmacological treatment for obesity, including eligibility, reimbursement pathways, and equity of access; and whether she will outline how medicines policy is being aligned with the objectives of that strategy. [10660/26]

344. Deputy David Cullinane asked the Minister for Health the number and the details of medications and medical products approved for reimbursement, but which received a recommendation to not consider the product for recommendation from an agency (details supplied), in tabular form. [10723/26]

345. Deputy David Cullinane asked the Minister for Health the reason pluvicto was not approved for reimbursement but luthathera received approval; and if she will make a statement on the matter. [10724/26]

1135. Deputy Aindrias Moynihan asked the Minister for Health when a NCPE re-commenced assessment will be completed (details supplied); and if she will make a statement on the matter. [10188/26]

1159. Deputy Shane Moynihan asked the Minister for Health for an update on the accessibility of Welireg (belzutifan) for patients with von Hippel-Lindau disease; and if she will make a statement on the matter. [10252/26]

1190. Deputy Pádraig Rice asked the Minister for Health the current reimbursement arrangements in place for GLP-1 medications; to identify the products currently available under each scheme and the criteria for access; if there are plans to expand access; if further products are undergoing pricing and reimbursement assessment; if so, the status of that work; and if she will make a statement on the…

1204. Deputy Mark Ward asked the Minister for Health if welireg is available to public HSE patients with von Hippel-Lindau disease; the way they can access this treatment; the alternative treatments that are offered through the HSE; and if she will make a statement on the matter. [10417/26]

984. Deputy Mairéad Farrell asked the Minister for Health the steps she has taken to ensure urgent access to Welireg (belzutifan) for a young adult with von Hippel-Lindau disease; whether compassionate or exceptional access mechanisms are available while national reimbursement processes are ongoing; the safeguards currently in place to protect such patients from avoidable permanent harm during adm…